- Home
- HUCK vs MNOV Comparison
HUCK vs MNOV Comparison
Compare HUCK & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HUCK | MNOV |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.5M | 137.8M |
| IPO Year | 2018 | 2004 |
Fundamental Metrics
Financial Performance| Metric | HUCK | MNOV |
|---|---|---|
| Price | $3.11 | $1.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $4.17 | ★ $8.25 |
| AVG Volume (30 Days) | ★ 777.6K | 393.5K |
| Earning Date | 12-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $318,857,000.00 | $2,360,807.00 |
| Revenue This Year | N/A | $78.20 |
| Revenue Next Year | $1.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.57 | ★ 194.15 |
| 52 Week Low | $2.98 | $1.17 |
| 52 Week High | $3.55 | $3.90 |
Technical Indicators
Market Signals| Indicator | HUCK | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 34.32 | 36.26 |
| Support Level | $3.00 | $1.29 |
| Resistance Level | $3.45 | $1.48 |
| Average True Range (ATR) | 0.13 | 0.11 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 29.47 | 1.55 |
Price Performance
Historical ComparisonAbout MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.